BR112015002760A2 - composição com fatores de crescimento, para ser usada no tratamento intranasal de uma doença neurodegenerativa ou outras doenças do sistema nervoso central, e seu método de fabricação - Google Patents
composição com fatores de crescimento, para ser usada no tratamento intranasal de uma doença neurodegenerativa ou outras doenças do sistema nervoso central, e seu método de fabricação Download PDFInfo
- Publication number
- BR112015002760A2 BR112015002760A2 BR112015002760A BR112015002760A BR112015002760A2 BR 112015002760 A2 BR112015002760 A2 BR 112015002760A2 BR 112015002760 A BR112015002760 A BR 112015002760A BR 112015002760 A BR112015002760 A BR 112015002760A BR 112015002760 A2 BR112015002760 A2 BR 112015002760A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- growth factor
- nervous system
- central nervous
- blood
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims abstract description 50
- 239000003102 growth factor Substances 0.000 claims abstract description 44
- 239000000126 substance Substances 0.000 claims abstract description 40
- 210000004369 blood Anatomy 0.000 claims abstract description 36
- 239000008280 blood Substances 0.000 claims abstract description 36
- 150000001875 compounds Chemical class 0.000 claims abstract description 31
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 26
- 238000011282 treatment Methods 0.000 claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 15
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 15
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 239000006228 supernatant Substances 0.000 claims description 17
- 108010088880 plasmagel Proteins 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 description 24
- 210000002381 plasma Anatomy 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 12
- 230000009261 transgenic effect Effects 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 6
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 210000001320 hippocampus Anatomy 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 210000001130 astrocyte Anatomy 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000003928 nasal cavity Anatomy 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 206010018341 Gliosis Diseases 0.000 description 3
- 208000037875 astrocytosis Diseases 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 210000001947 dentate gyrus Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000004766 neurogenesis Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 206010002942 Apathy Diseases 0.000 description 2
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 2
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000007341 astrogliosis Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 210000001787 dendrite Anatomy 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000196 olfactory nerve Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- -1 EDGE Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 241000539716 Mea Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 210000000576 arachnoid Anatomy 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 238000013017 mechanical damping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008655 medium-term memory Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003446 pia mater Anatomy 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000000678 plasma activation Methods 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201200810A ES2442242B1 (es) | 2012-08-09 | 2012-08-09 | Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación. |
| PCT/ES2013/000176 WO2014023860A1 (es) | 2012-08-09 | 2013-07-19 | Composición con factores de crecimiento obtenidos a partir del plasma sanguíneo destinada al tratamiento de enfermedades neurodegenerativas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015002760A2 true BR112015002760A2 (pt) | 2020-04-22 |
Family
ID=49111229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015002760A BR112015002760A2 (pt) | 2012-08-09 | 2013-07-19 | composição com fatores de crescimento, para ser usada no tratamento intranasal de uma doença neurodegenerativa ou outras doenças do sistema nervoso central, e seu método de fabricação |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20140044795A1 (https=) |
| EP (1) | EP2883569B1 (https=) |
| JP (1) | JP6339568B2 (https=) |
| KR (1) | KR102149162B1 (https=) |
| CN (1) | CN104519961A (https=) |
| AR (1) | AR092086A1 (https=) |
| BR (1) | BR112015002760A2 (https=) |
| CA (1) | CA2881075A1 (https=) |
| CL (1) | CL2014003510A1 (https=) |
| CO (1) | CO7170177A2 (https=) |
| ES (2) | ES2442242B1 (https=) |
| IN (1) | IN2014MN02675A (https=) |
| MX (1) | MX357828B (https=) |
| PE (1) | PE20150616A1 (https=) |
| RU (1) | RU2696497C2 (https=) |
| TW (1) | TWI649084B (https=) |
| WO (1) | WO2014023860A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2016003282A1 (es) | 2016-12-21 | 2017-08-18 | Univ Chile | Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2252993T3 (es) * | 1998-12-09 | 2006-05-16 | Chiron Corporation | Administracion de agentes neurotroficos al sistema nervioso central. |
| AR022333A1 (es) * | 1999-01-26 | 2002-09-04 | Anitua Aldecoa Eduardo | Regenerador de tejido oseo |
| US6811777B2 (en) * | 2002-04-13 | 2004-11-02 | Allan Mishra | Compositions and minimally invasive methods for treating incomplete connective tissue repair |
| US7608258B2 (en) * | 2002-04-13 | 2009-10-27 | Allan Mishra | Method for treatment of tendinosis using platelet rich plasma |
| ES2221770B2 (es) | 2002-04-19 | 2006-07-16 | Eduardo Anitua Aldecoa | Metodo de preparacion de un compuesto para la regeneracion de tejidos. |
| US20060004189A1 (en) * | 2004-07-02 | 2006-01-05 | James Gandy | Compositions for treating wounds and processes for their preparation |
| CA2620202C (en) * | 2005-08-26 | 2016-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Therapy procedure for drug delivery for trigeminal pain |
| EP2152240A4 (en) * | 2007-06-08 | 2012-05-09 | Healthpartners Res Foundation | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR REINFORCED TARGETING OF THERAPEUTIC COMPOUNDS TO THE CENTRAL NERVOUS SYSTEM |
| ES2333498B1 (es) * | 2007-08-02 | 2011-01-10 | Biotechnology Institute, I Mas D, S.L. | Metodo y compuesto para el tratamiento de enfermedades o dolencias articulares o para el tratamiento de la piel con fines esteticos u otros, y el metodo de preparacion del compuesto. |
| EP2212344B1 (en) * | 2007-09-14 | 2014-03-26 | Formycon AG | Use of slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases |
| MX2011011921A (es) | 2009-05-14 | 2011-12-06 | Biotechnology Inst I Mas D Sl | Metodo para la preparacion de al menos un compuesto a partir de sangre, y dispositivo de extraccion para ser utilizado en la ejecucion de dicho metodo. |
| KR101114712B1 (ko) * | 2009-10-23 | 2012-02-29 | 세원셀론텍(주) | 염화칼슘용액과 제1형 콜라겐으로 혈소판풍부혈장(ｐｒｐ)을 활성화하여 조직재생을 유도하는 조성물의 제조방법 |
| ES2369945B1 (es) | 2011-07-29 | 2012-10-15 | Eduardo Anitua Aldecoa | Procedimiento de obtención de una composición que contiene factores de crecimiento a partir de un compuesto sanguíneo, y composición obtenible por dicho procedimiento. |
-
2012
- 2012-08-09 ES ES201200810A patent/ES2442242B1/es not_active Expired - Fee Related
-
2013
- 2013-07-19 BR BR112015002760A patent/BR112015002760A2/pt not_active Application Discontinuation
- 2013-07-19 CA CA2881075A patent/CA2881075A1/en not_active Abandoned
- 2013-07-19 CN CN201380041280.4A patent/CN104519961A/zh active Pending
- 2013-07-19 RU RU2015104076A patent/RU2696497C2/ru active
- 2013-07-19 TW TW102125858A patent/TWI649084B/zh not_active IP Right Cessation
- 2013-07-19 WO PCT/ES2013/000176 patent/WO2014023860A1/es not_active Ceased
- 2013-07-19 JP JP2015525915A patent/JP6339568B2/ja not_active Expired - Fee Related
- 2013-07-19 MX MX2015001677A patent/MX357828B/es active IP Right Grant
- 2013-07-19 ES ES13756518.0T patent/ES2662385T3/es active Active
- 2013-07-19 KR KR1020157001551A patent/KR102149162B1/ko not_active Expired - Fee Related
- 2013-07-19 EP EP13756518.0A patent/EP2883569B1/en not_active Not-in-force
- 2013-07-19 PE PE2015000116A patent/PE20150616A1/es not_active Application Discontinuation
- 2013-08-08 US US13/962,340 patent/US20140044795A1/en not_active Abandoned
- 2013-08-08 AR ARP130102835A patent/AR092086A1/es unknown
-
2014
- 2014-12-23 CL CL2014003510A patent/CL2014003510A1/es unknown
- 2014-12-31 IN IN2675MUN2014 patent/IN2014MN02675A/en unknown
-
2015
- 2015-01-20 CO CO15010369A patent/CO7170177A2/es unknown
-
2016
- 2016-03-08 US US15/063,969 patent/US20160184360A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014023860A1 (es) | 2014-02-13 |
| MX2015001677A (es) | 2015-04-10 |
| EP2883569A1 (en) | 2015-06-17 |
| CL2014003510A1 (es) | 2015-05-04 |
| IN2014MN02675A (https=) | 2015-08-28 |
| ES2442242B1 (es) | 2014-11-25 |
| TWI649084B (zh) | 2019-02-01 |
| EP2883569B1 (en) | 2017-12-20 |
| ES2442242A1 (es) | 2014-02-10 |
| ES2662385T3 (es) | 2018-04-06 |
| KR102149162B1 (ko) | 2020-08-31 |
| JP2015524464A (ja) | 2015-08-24 |
| MX357828B (es) | 2018-07-25 |
| TW201408310A (zh) | 2014-03-01 |
| AR092086A1 (es) | 2015-03-25 |
| RU2015104076A (ru) | 2016-09-27 |
| US20140044795A1 (en) | 2014-02-13 |
| PE20150616A1 (es) | 2015-05-25 |
| JP6339568B2 (ja) | 2018-06-06 |
| CA2881075A1 (en) | 2014-02-13 |
| CN104519961A (zh) | 2015-04-15 |
| CO7170177A2 (es) | 2015-01-28 |
| KR20150040860A (ko) | 2015-04-15 |
| RU2696497C2 (ru) | 2019-08-02 |
| US20160184360A1 (en) | 2016-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Haberland et al. | Encephalocraniocutaneous lipomatosis: a new example of ectomesodermal dysgenesis | |
| Vass et al. | Capsaicin stimulation of the cochlea and electric stimulation of the trigeminal ganglion mediate vascular permeability in cochlear and vertebro-basilar arteries: a potential cause of inner ear dysfunction in headache | |
| ES2307975T3 (es) | Composiciones analgesicas que comprenden antagonistas del receptor de nmda y cloruro de benzalconio. | |
| Goadsby et al. | The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: ac‐fos immunocytochemical study | |
| BRPI0710858A2 (pt) | uso de uma proteìna anti-secretora, um derivado, homólogo e/ou fragmento da mesma, tendo atividade anti-secretora, e/ou um sal farmaceuticamente ativo da mesma | |
| BRPI0804623B1 (pt) | Uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos | |
| JP2019506439A (ja) | ターゲティングされた治療用リソソーム酵素融合タンパク質、関連する製剤、およびその使用 | |
| Karaoğlan et al. | A comparison of the clinical efficacy of GON block at the C2 level and GON block at the classical distal occipital level in the treatment of migraine | |
| Tshamala et al. | True dermoid wst in a Rhodesian ridgeback | |
| BR112020000115A2 (pt) | sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos | |
| Lee et al. | Functional recovery after injury of motor cortex in rats: effects of rehabilitation and stem cell transplantation in a traumatic brain injury model of cortical resection | |
| BR112015002760A2 (pt) | composição com fatores de crescimento, para ser usada no tratamento intranasal de uma doença neurodegenerativa ou outras doenças do sistema nervoso central, e seu método de fabricação | |
| ES2991899T3 (es) | Nanopartículas para su uso para el tratamiento de un trastorno neuronal | |
| Xiao et al. | The efficacy of cerebrolysin in patients with vascular dementia: Results of a Chinese multicentre, randomised, double-blind, placebo-controlled trial | |
| Fujii et al. | Spinal cord stimulation therapy at an early stage for unresponsive patients with hypoxic encephalopathy | |
| CN106265112B (zh) | 促进伤口愈合的药物或化妆用组合物 | |
| Rao et al. | Sturge–Weber syndrome coexisting with multiple vertebral vascular malformations and hemivertebra with scoliosis and upper limb and ear hypertrophy | |
| Gayan-Ramirez et al. | Inotropic effects of aminophylline on canine diaphragm are enhanced by hyperinflation | |
| Eseoğlu et al. | Cranial hyperthermia resulting from decreased parotid gland salivation induced by ischemic degeneration of glossopharyngeal network in subarachnoid hemorrhage: Cranial hyperthermia resulting from decreased parotid gland salivation | |
| Erickson | Neurogenic hyperthermia. | |
| Junge et al. | Diagnosis of severe traumatic brain injury using multimodal imaging in a donkey | |
| Bito | Transport Functions of the Blood—Ocular and Blood—Brain Barriers, and the Microenvironment of Neuronal and non-neuronal Tissues | |
| KR20240090983A (ko) | 신경 복원 촉진에 사용되는 이소로이폴린 및 그 유도체의 용도 | |
| BR112019012984A2 (pt) | nanopartículas para uso para tratar um transtorno neuronal | |
| Swati et al. | A critical review on nasal drug delivery system in Ayurveda: Nasya |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |